Study of orBec (Registered Trademark (R)) With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

This trial is studying a drug called orBec alongside standard prednisone treatment for graft-versus-host disease (GVHD) affecting the gut. GVHD happens when immune cells from a donated bone marrow or stem cell transplant attack the recipient's own body. OrBec is a steroid that works locally in the gut with fewer whole-body side effects, which could make treatment safer. You may be eligible if: - You are 18 years of age or older - You have received an allogeneic (donor) stem cell or bone marrow transplant - You have been diagnosed with gastrointestinal GVHD - You do not have a gut infection - You are able to swallow tablets and use adequate birth control You may NOT be eligible if: - You have significant GVHD of the skin or liver - You have persistent vomiting - You are HIV positive - You are pregnant or breastfeeding Talk to your doctor about whether this trial might be right for you.